Greetings from the US HAEA Angioedema Center,
Drs Z, R and I will be attending the WSAAI conference this week. I hope to send you updates on HAE information presented at the gathering. We will be back with a new QOTW in February.
I would like to take the opportunity to observe a landmark. The Center will celebrate the one-year anniversary of the Grand Opening on the 31st. I wish to thank the HAEA for its tireless support of our efforts along with our dedicated staff. We recognize the Center Endowment Gifts from Shire—which now has incorporated Viropharma and Dyax, CSL Behering and BioCryst. We would also like to express our gratitude for the generous gift from Valeant pharmaceuticals. It is really through the combined efforts of all that the Center became a reality.
Highlights since the opening include the successful completion of 6 clinical trials for novel therapies for HAE. We will have two new trials starting soon which will hopefully further expand the options for care of HAE. Beyond the Center we have been working to advance understanding of HAE with organizing a R13 NIH interdisciplinary conference “Expanding our HAE Boundaries”, and in cooperation with the HAEA the second international HAE-normal C1 inhibitor consensus conference. Multiple lectures have been given to enlighten physicians and patients about HAE including the HAEA Patient Summit, AAAAI, ACAAI, Regional Allergy Societies, Grand Rounds and this week at the WSAAI. We have also been busy with publications on a range of topics including the clinical expression of HAE, pathophysiology and approach to care.
At the “Center” of it all is you—the patients. It is our privilege to care for you and share the journey to the ultimate goal of a normal life for all with HAE.